Naslov
Later introduction of bevacizumab is independent predictor of metastatic colorectal cancer progression; Croatian prospective cohort study.

Autori
Pavlović, Mirjana ; Tečić Vuger, Ana ; Silovski, Tajana ; Jurić, Andreja ; Bajić, Žarko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
CEOC 2016 Book of Abstracts / - , 2016, 72-72

Skup
12th Central European Oncology Congress A Best of ASCO®

Mjesto i datum
Opatija, Hrvatska, 22.06.2016. - 25.06.2016

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
metastatic colorectal cancer, bevacizumab

Sažetak
Colorectal cancer is the third most common cancer in Europe. At the time of diagnosis 20% of patients have advanced disease. Risk of recurrence during the first 18 months after surgery is 18%. Bevacizumab prolongs progression free and overall survival in metastatic colorectal cancer. The objective of our study was to determine whether the time of introduction of bevacizumab affects the time to progression of metastatic disease in real-life clinical settings. In conclusion, our study has shown, in real-life clinical settings, that the time from diagnosis of metastatic disease to the initiation of bevacizumab is associated with higher risk of metastatic colorectal cancer progression within the first 12 months.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA